| Literature DB >> 33248854 |
Joseane C de Castro1, Laila V de Almeida1, Mariana Santos Cardoso1, Fabricio M Silva Oliveira1, Denise S Nogueira1, João Luis Reis-Cunha1, Luisa M D Magalhaes1, Bin Zhan2, Maria Elena Bottazzi3, Peter J Hotez3, Lilian L Bueno1, Daniella Castanheira Bartholomeu1, Ricardo T Fujiwara4.
Abstract
An estimated 400 million people are infected by parasites of the genus Ascaris and the existing control measures are inefficient. Vaccine development using B cell antigens is a promising strategy for increased protection against this parasite. The present study aimed at developing a chimeric protein capable of conferring protection against infection by Ascaris sp. For this purpose, we performed B-cell epitope predictions on previously described vaccine candidate proteins from Ascaris suum and the corresponding peptides were used to construct a chimeric protein. Female BALB / c mice were immunized subcutaneously in three doses at 10 day intervals with a vaccine formulation comprised of the chimeric protein together with monophosphoryl lipid A (MPLA). Control groups included protein alone, MPLA, or PBS. After challenge infection, animals vaccinated with chimeric protein plus MPLA showed a reduction of 73.54% of larval load in the lung compared to control group animals. Animals immunized with chimeric protein plus MPLA also display higher IgG response and a reduction in lung inflammation. Our study highlights how chimeric proteins containing more than one B cell epitope can enhance immune protection against helminthic infection and offer new approaches to the development of Ascaris vaccines.Entities:
Keywords: Antigens; Ascaris sp.; B cell epitopes; Chimeric antigens; IgG response
Mesh:
Substances:
Year: 2020 PMID: 33248854 DOI: 10.1016/j.vaccine.2020.11.046
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641